Compass Therapeutics (CMPX) Assets Average (2018 - 2026)

Compass Therapeutics has reported Assets Average for 9 years, with the latest figure at $212.4 million in Q1 2026.

• Quarterly Assets Average rose 56.24% year-over-year to $212.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $212.4 million (up 56.24% YoY) and the FY2025 annual result came in at $180.0 million, up 21.1% from the prior year.
• Assets Average fell to $212.4 million in Q1 2026 per CMPX's latest filing, from $225.4 million in the prior quarter.
• Over five years, Assets Average peaked at $225.4 million in Q4 2025 and troughed at $124.1 million in Q2 2025.
• A 5-year average of $164.3 million and a median of $159.0 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2025: Assets Average soared 199.99% in 2022, then fell 21.66% in 2025.
• Over 5 years, Assets Average stood at $163.7 million in 2022, then declined by 0.17% to $163.5 million in 2023, then dropped by 11.43% to $144.8 million in 2024, then soared by 55.7% to $225.4 million in 2025, then dropped by 5.79% to $212.4 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $212.4 million, $225.4 million, and $174.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.